JP2015515491A - β−アミロイドの体外的減少のための新規組成物及びその製造方法 - Google Patents
β−アミロイドの体外的減少のための新規組成物及びその製造方法 Download PDFInfo
- Publication number
- JP2015515491A JP2015515491A JP2015508893A JP2015508893A JP2015515491A JP 2015515491 A JP2015515491 A JP 2015515491A JP 2015508893 A JP2015508893 A JP 2015508893A JP 2015508893 A JP2015508893 A JP 2015508893A JP 2015515491 A JP2015515491 A JP 2015515491A
- Authority
- JP
- Japan
- Prior art keywords
- amyloid
- blood
- peptide
- dialysate
- capture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims abstract description 86
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000000338 in vitro Methods 0.000 title description 5
- 230000009467 reduction Effects 0.000 title description 3
- 210000004369 blood Anatomy 0.000 claims abstract description 94
- 239000008280 blood Substances 0.000 claims abstract description 94
- 239000011230 binding agent Substances 0.000 claims abstract description 73
- 239000012528 membrane Substances 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 63
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 238000001914 filtration Methods 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 208000024827 Alzheimer disease Diseases 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 15
- 238000009739 binding Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000003440 toxic substance Substances 0.000 claims description 12
- 238000001631 haemodialysis Methods 0.000 claims description 11
- 230000000322 hemodialysis Effects 0.000 claims description 11
- 231100000614 poison Toxicity 0.000 claims description 11
- 239000011148 porous material Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 239000002581 neurotoxin Substances 0.000 claims description 10
- 231100000618 neurotoxin Toxicity 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 8
- 101710138657 Neurotoxin Proteins 0.000 claims description 7
- 238000002615 hemofiltration Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010044688 Trisomy 21 Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000000385 dialysis solution Substances 0.000 claims description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000000502 dialysis Methods 0.000 abstract description 58
- 108010075875 amyloid beta-protein (16-20) Proteins 0.000 abstract description 15
- 230000036541 health Effects 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 210000004379 membrane Anatomy 0.000 description 46
- 210000002381 plasma Anatomy 0.000 description 45
- 239000000306 component Substances 0.000 description 30
- 239000000499 gel Substances 0.000 description 16
- 239000012466 permeate Substances 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 241000601295 Bairdiella ronchus Species 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 5
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 239000012510 hollow fiber Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 231100000189 neurotoxic Toxicity 0.000 description 4
- 230000002887 neurotoxic effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004087 circulation Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010001526 Air embolism Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- PTJWCLYPVFJWMP-UHFFFAOYSA-N 2-[[3-hydroxy-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical group OCC(CO)(CO)COCC(CO)(CO)COCC(CO)(CO)CO PTJWCLYPVFJWMP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102100034004 Gamma-adducin Human genes 0.000 description 1
- 101000799011 Homo sapiens Gamma-adducin Proteins 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- External Artificial Organs (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638672P | 2012-04-26 | 2012-04-26 | |
| US61/638,672 | 2012-04-26 | ||
| PH1/2013/000037A PH12013000037A1 (en) | 2013-01-30 | 2013-01-30 | Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof |
| PCT/PH2013/000005 WO2013162387A1 (en) | 2012-04-26 | 2013-01-30 | Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof |
| PH1-2013-000037 | 2013-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2015515491A true JP2015515491A (ja) | 2015-05-28 |
Family
ID=49483563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015508893A Pending JP2015515491A (ja) | 2012-04-26 | 2013-01-30 | β−アミロイドの体外的減少のための新規組成物及びその製造方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20150087591A1 (enExample) |
| EP (1) | EP2841447B1 (enExample) |
| JP (1) | JP2015515491A (enExample) |
| KR (2) | KR20150022753A (enExample) |
| CN (2) | CN104662032A (enExample) |
| AU (2) | AU2013253098A1 (enExample) |
| CA (1) | CA2871585A1 (enExample) |
| DK (1) | DK2841447T3 (enExample) |
| ES (1) | ES2685374T3 (enExample) |
| HR (1) | HRP20181365T1 (enExample) |
| IN (1) | IN2014MN02137A (enExample) |
| LT (1) | LT2841447T (enExample) |
| PH (1) | PH12013000037A1 (enExample) |
| PL (1) | PL2841447T3 (enExample) |
| RS (1) | RS57651B1 (enExample) |
| SG (1) | SG11201406972UA (enExample) |
| SI (1) | SI2841447T1 (enExample) |
| SM (1) | SMT201800445T1 (enExample) |
| WO (1) | WO2013162387A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106800590B (zh) * | 2015-11-25 | 2021-04-09 | 杭州智鹤丹谷生物医药有限公司 | 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用 |
| CN105651840B (zh) * | 2016-04-01 | 2017-12-26 | 商丘师范学院 | 一种检测β‑淀粉样蛋白寡聚体的类免疫电化学传感器及其制备方法 |
| CN109954128A (zh) * | 2019-03-08 | 2019-07-02 | 南开大学 | 一种可干扰β-淀粉样蛋白聚集并协助清除的功能化纳米凝胶及制备方法 |
| CN114933635B (zh) * | 2021-08-29 | 2023-05-19 | 武汉夫图生物科技有限公司 | 纳米小肽fh及其在制备治疗及预防眼底血管疾病药物中的应用 |
| US20230201438A1 (en) * | 2021-12-23 | 2023-06-29 | Fresenius Medical Care Holdings, Inc. | Compounds, systems, and techniques for removal of peripheral amyloid beta peptide with albumin binding competitors |
| CN115337388A (zh) * | 2022-07-01 | 2022-11-15 | 南方医科大学 | 一种抗菌和预防hpv病毒的按需释放凝胶及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060069010A1 (en) * | 2003-10-17 | 2006-03-30 | Senicure Llc | Detoxification depot for Alzheimer's disease |
| US20070010435A1 (en) * | 2002-12-19 | 2007-01-11 | New York University | Method for treating amyloid disease |
| US20070092508A1 (en) * | 2005-10-21 | 2007-04-26 | Recombiant Technologies, Llc | Detoxification depot for Alzheimer's disease |
| WO2011063156A2 (en) * | 2009-11-18 | 2011-05-26 | Nektar Therapeutics | Acid salt forms of polymer-drug conjugates and alkoxylation methods |
| WO2011075953A1 (zh) * | 2009-12-25 | 2011-06-30 | 天津键凯科技有限公司 | 多臂聚乙二醇衍生物及其与药物的结合物和凝胶 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5223199B2 (enExample) * | 1972-05-27 | 1977-06-22 | ||
| JPS4942189A (enExample) * | 1972-08-29 | 1974-04-20 | ||
| CA2214247C (en) * | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| JPH09157283A (ja) * | 1995-12-13 | 1997-06-17 | Tatsuaki Yamaguchi | 燐酸吸着コロイド |
| US6022859A (en) * | 1996-11-15 | 2000-02-08 | Wisconsin Alumni Research Foundation | Inhibitors of β-amyloid toxicity |
| JP5843345B2 (ja) * | 2010-07-08 | 2016-01-13 | 旭化成メディカル株式会社 | β−アミロイド除去システム |
-
2013
- 2013-01-30 IN IN2137MUN2014 patent/IN2014MN02137A/en unknown
- 2013-01-30 DK DK13781268.1T patent/DK2841447T3/en active
- 2013-01-30 HR HRP20181365TT patent/HRP20181365T1/hr unknown
- 2013-01-30 KR KR20147030161A patent/KR20150022753A/ko not_active Ceased
- 2013-01-30 KR KR1020187030342A patent/KR20180117226A/ko not_active Ceased
- 2013-01-30 CN CN201380027665.5A patent/CN104662032A/zh active Pending
- 2013-01-30 PH PH1/2013/000037A patent/PH12013000037A1/en unknown
- 2013-01-30 ES ES13781268.1T patent/ES2685374T3/es active Active
- 2013-01-30 SM SM20180445T patent/SMT201800445T1/it unknown
- 2013-01-30 JP JP2015508893A patent/JP2015515491A/ja active Pending
- 2013-01-30 PL PL13781268T patent/PL2841447T3/pl unknown
- 2013-01-30 WO PCT/PH2013/000005 patent/WO2013162387A1/en not_active Ceased
- 2013-01-30 US US14/397,486 patent/US20150087591A1/en not_active Abandoned
- 2013-01-30 CN CN201811292445.6A patent/CN109731169A/zh active Pending
- 2013-01-30 LT LTEP13781268.1T patent/LT2841447T/lt unknown
- 2013-01-30 EP EP13781268.1A patent/EP2841447B1/en active Active
- 2013-01-30 SG SG11201406972UA patent/SG11201406972UA/en unknown
- 2013-01-30 AU AU2013253098A patent/AU2013253098A1/en not_active Abandoned
- 2013-01-30 SI SI201331147T patent/SI2841447T1/sl unknown
- 2013-01-30 RS RS20181008A patent/RS57651B1/sr unknown
- 2013-01-30 CA CA2871585A patent/CA2871585A1/en active Pending
-
2016
- 2016-07-25 AU AU2016208257A patent/AU2016208257B2/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070010435A1 (en) * | 2002-12-19 | 2007-01-11 | New York University | Method for treating amyloid disease |
| US20060069010A1 (en) * | 2003-10-17 | 2006-03-30 | Senicure Llc | Detoxification depot for Alzheimer's disease |
| US20070092508A1 (en) * | 2005-10-21 | 2007-04-26 | Recombiant Technologies, Llc | Detoxification depot for Alzheimer's disease |
| WO2011063156A2 (en) * | 2009-11-18 | 2011-05-26 | Nektar Therapeutics | Acid salt forms of polymer-drug conjugates and alkoxylation methods |
| WO2011075953A1 (zh) * | 2009-12-25 | 2011-06-30 | 天津键凯科技有限公司 | 多臂聚乙二醇衍生物及其与药物的结合物和凝胶 |
Non-Patent Citations (5)
| Title |
|---|
| BRIAN M ET AL.: "Designing Peptide Inhibitors for Oligomerization and Toxicity of Alzheimer's β-Amyloid Peptide", BIOCHEMISTRY, vol. Vol.47, JPN6015049083, 12 January 2008 (2008-01-12), pages 1984-1992 * |
| CURRENT ALZHEIMER RESEAECH, vol. 5(1), JPN7017001221, 2008, pages 26-32 * |
| MARTA J. KRYSMANN ET AL.: "Self-Assembly and Hydrogelation of an Amyloid Peptide Fragment", BIOCHEMISTRY, vol. Vol.47, JPN6015049087, 28 March 2008 (2008-03-28), pages 4597-4605 * |
| MERCE BOADA ET AL.: "AMYLOID-TARGETED THERAPEUTICS IN ALZHEIMER'S DISEASE: USE OF HUMAN ALBUMIN IN PLASMA EXCHANGE AS A N", DRUG NEWS PERSPECT, vol. 22, no. 6, JPN6015049090, July 2009 (2009-07-01), pages 325-339, XP009145785, DOI: doi:10.1358/dnp.2009.22.6.1395256 * |
| 北口 暢哉、川口 和紀: "トピックス アルツハイマー病治療システム 血液からのＡβ除去によるアルツハイマー病治療システムの創製", ＰＥＴ ＪＯＵＲＮＡＬ, vol. 第１４号, JPN6015049084, June 2011 (2011-06-01), pages １０−１１頁 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2841447A4 (en) | 2015-10-28 |
| CN104662032A (zh) | 2015-05-27 |
| LT2841447T (lt) | 2018-09-10 |
| DK2841447T3 (en) | 2018-09-03 |
| ES2685374T3 (es) | 2018-10-08 |
| AU2016208257A1 (en) | 2016-08-11 |
| SI2841447T1 (sl) | 2018-10-30 |
| SMT201800445T1 (it) | 2018-09-13 |
| CA2871585A1 (en) | 2013-10-31 |
| SG11201406972UA (en) | 2014-11-27 |
| KR20150022753A (ko) | 2015-03-04 |
| AU2016208257B2 (en) | 2018-08-16 |
| HRP20181365T1 (hr) | 2018-10-19 |
| US20150087591A1 (en) | 2015-03-26 |
| EP2841447B1 (en) | 2018-06-13 |
| RS57651B1 (sr) | 2018-11-30 |
| KR20180117226A (ko) | 2018-10-26 |
| CN109731169A (zh) | 2019-05-10 |
| EP2841447A1 (en) | 2015-03-04 |
| IN2014MN02137A (enExample) | 2015-08-21 |
| PL2841447T3 (pl) | 2019-03-29 |
| AU2013253098A1 (en) | 2014-11-13 |
| PH12013000037A1 (en) | 2013-10-14 |
| WO2013162387A1 (en) | 2013-10-31 |
| AU2013253098A2 (en) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harm et al. | Cytokine removal in extracorporeal blood purification: an in vitro study | |
| AU2016208257B2 (en) | Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof | |
| KR102211104B1 (ko) | 혈액투석여과장치 | |
| EP1852136A1 (en) | Use of a dialysis membrane for preparing a haemodialysis unit for reducing blood free light chain concentration | |
| WO2015095553A1 (en) | Methods and apparatus for kidney dialysis | |
| EP2238079A2 (en) | Method and apparatus for increasing contaminant clearance rates during extracorporeal fluid treatment | |
| AT413336B (de) | Apherese-vorrichtung | |
| US20230036583A1 (en) | Devices and methods for reducing rejection of a transplanted organ in a recipient | |
| EP2077869B1 (en) | A system for the extra-corporeal purification of blood of pathogenic enzymes | |
| JP4201313B2 (ja) | 有害物質結合アルブミン除去システム | |
| AU2014101449A4 (en) | Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof | |
| JP4947693B2 (ja) | アルブミンとアルブミンに結合した生体分子の分離方法 | |
| RU2269363C1 (ru) | Способ лечения печеночной недостаточности | |
| JP6337175B2 (ja) | 急性又は慢性腎不全患者の血液からタンパク質結合毒素を除去するための透析法に使用される医薬組成物。 | |
| Zhao et al. | In Vivo Evaluation and Application of Adsorbents for Hemoperfusion | |
| Cocchi et al. | Transport phenomena in dialysis processes | |
| JP6857957B2 (ja) | 腎臓透析および体外解毒に関する方法および装置 | |
| Nalesso et al. | Plasma Filtration Adsorption Dialysis: A New Experimental Approach to Treatment of Sepsis and MOF | |
| JPH0385171A (ja) | 肝炎治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141225 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150310 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160405 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160712 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161222 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170104 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170407 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180307 |